{"id":"NCT03566238","sponsor":"Albireo","briefTitle":"This Study Will Investigate the Efficacy and Safety of A4250 in Children With PFIC Types 1 or 2","officialTitle":"A Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study to Demonstrate Efficacy and Safety of A4250 in Children With Progressive Familial Intrahepatic Cholestasis Types 1 and 2 (PEDFIC 1)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-05-16","primaryCompletion":"2020-07-27","completion":"2020-07-28","firstPosted":"2018-06-25","resultsPosted":"2021-09-05","lastUpdate":"2021-09-05"},"enrollment":62,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["PFIC1","PFIC2"],"interventions":[{"type":"DRUG","name":"A4250 (odevixibat)","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"A4250 low dose","type":"EXPERIMENTAL"},{"label":"A4250 high dose","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Double blind, randomized, placebo controlled, Phase 3 study to investigate the efficacy and safety of low doses and high doses of A4250 compared to placebo in children with progressive familial intrahepatic cholestasis (PFIC) types 1 and 2.","primaryOutcome":{"measure":"Proportion of Positive Pruritus Assessments at the Participant Level Over the 24-week Treatment Period Based on the Albireo Observer-reported Outcome (ObsRO) Instrument (United States Primary Endpoint)","timeFrame":"Over 24 weeks of treatment","effectByArm":[{"arm":"A4250 Low Dose","deltaMin":58.34,"sd":8.58},{"arm":"A4250 High Dose","deltaMin":51.81,"sd":9.459},{"arm":"Placebo","deltaMin":30.1,"sd":9.119}],"pValues":[{"comp":"OG000 vs OG002","p":"0.0019"},{"comp":"OG001 vs OG002","p":"0.0163"}]},"eligibility":{"minAge":"6 Months","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":10},"locations":{"siteCount":45,"countries":["United States","Australia","Belgium","Canada","France","Germany","Israel","Italy","Netherlands","Poland","Saudi Arabia","Spain","Sweden","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["36066745","35780807"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":23},"commonTop":["Pyrexia","Diarrhoea","Upper respiratory tract infection","Vomiting","Alanine aminotransferase increased"]}}